THE BLOOD FACTOR
-
Gene therapy for hemophilia B one step closer: CSL Behring and pCPA agree on pricing
MONTREAL, October 7, 2025 – CSL Behring Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) have announced signing of a Letter of Intent that sets pricing...
-
Update on novel therapies for hemophilia A and B
MONTRÉAL, September 19, 2025 – No announcements have been made over the summer on progress in gaining access to two novel hemophilia therapies. Altuviiio for...
-
Reimbursement of Altuviiio recommended, but…
MONTRÉAL, July 3, 2025 – In June, both Canada’s Drug Agency (CDA) and Quebec’s Institut national d’excellence en santé et en services sociaux (INESSS) released...
-
Hemgenix 4-year results show steady durability
MONTREAL, March 12, 2025 – Results from the HOPE-B trial for the hemophilia B gene therapy, Hemgenix, show steady expression of factor IX (FIX) four...
-
Development halts in first-generation gene therapies
MONTREAL, February 25, 2025 – On February 20, Pfizer announced that it was stopping development of its hemophilia B gene therapy, Beqvez. It cited “soft...